Dr David Welsh

  • Honorary Research Fellow (Institute of Cardiovascular & Medical Sciences)

email: David.Welsh@glasgow.ac.uk

Scottish Pulmonary Vascular Unit, Room C210, Dept of Biological and Biomedical Sciences, Charles Oakley Building, G4 0BA G4 0BA

Publications

List by: Type | Date

Jump to: 2020 | 2017 | 2015 | 2014 | 2012 | 2009 | 2008 | 2007
Number of items: 10.

2020

Wilson, K. S. et al. (2020) Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation, 10(2), (doi: 10.1177/2045894020922810)

Welsh, D. (2020) Exploring the failing right ventricle in pulmonary hypertension by CMR: An in vivo animal study utilising Macitentan. Journal of the American Heart Association, (Accepted for Publication)

2017

Kurowska-Stolarska, M. et al. (2017) The role of microRNA-155/LXR pathway in experimental and Idiopathic Pulmonary Fibrosis. Journal of Allergy and Clinical Immunology, 139(6), pp. 1946-1956. (doi: 10.1016/j.jaci.2016.09.021) (PMID:27746237) (PMCID:PMC5457127)

2015

Church, A. C., Martin, D. H., Wadsworth, R., Bryson, G., Fisher, A. J., Welsh, D. J. and Peacock, A. J. (2015) The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 309(4), L333-L347. (doi: 10.1152/ajplung.00038.2015) (PMID:26024891) (PMCID:PMC4538235)

2014

Shao, D. et al. (2014) Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 451(1), pp. 8-14. (doi: 10.1016/j.bbrc.2014.06.111) (PMID:25003325)

2012

Carlin, C., Celnik, D., Pak, O., Wadsworth, R., Peacock, A. and Welsh, D. (2012) Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 47(2), pp. 140-148. (doi: 10.1165/rcmb.2011-0411OC)

2009

Weerackody, R. P., Welsh, D. J., Wadsworth, R. M. and Peacock, A. J. (2009) Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology: Heart and Circulatory Physiology, 296(5), H1312-H1320. (doi: 10.1152/ajpheart.00977.2008)

2008

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117(22), pp. 2928-2937. (doi: 10.1161/CIRCULATIONAHA.108.767558)

Syyed, R., Reeves, J. T., Welsh, D., Raeside, D., Johnson, M. K. and Peacock, A. J. (2008) The Relationship Between the Components of Pulmonary Artery Pressure Remains Constant Under All Conditions in Both Health and Disease. Chest, 133(3), pp. 633-639. (doi: 10.1378/chest.07-1367)

2007

Carlin, C., Peacock, A. and Welsh, D. (2007) Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 37(4), pp. 447-456. (doi: 10.1165/rcmb.2007-0012OC)

This list was generated on Mon Dec 6 19:54:16 2021 GMT.
Jump to: Articles
Number of items: 10.

Articles

Wilson, K. S. et al. (2020) Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation, 10(2), (doi: 10.1177/2045894020922810)

Welsh, D. (2020) Exploring the failing right ventricle in pulmonary hypertension by CMR: An in vivo animal study utilising Macitentan. Journal of the American Heart Association, (Accepted for Publication)

Kurowska-Stolarska, M. et al. (2017) The role of microRNA-155/LXR pathway in experimental and Idiopathic Pulmonary Fibrosis. Journal of Allergy and Clinical Immunology, 139(6), pp. 1946-1956. (doi: 10.1016/j.jaci.2016.09.021) (PMID:27746237) (PMCID:PMC5457127)

Church, A. C., Martin, D. H., Wadsworth, R., Bryson, G., Fisher, A. J., Welsh, D. J. and Peacock, A. J. (2015) The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 309(4), L333-L347. (doi: 10.1152/ajplung.00038.2015) (PMID:26024891) (PMCID:PMC4538235)

Shao, D. et al. (2014) Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 451(1), pp. 8-14. (doi: 10.1016/j.bbrc.2014.06.111) (PMID:25003325)

Carlin, C., Celnik, D., Pak, O., Wadsworth, R., Peacock, A. and Welsh, D. (2012) Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 47(2), pp. 140-148. (doi: 10.1165/rcmb.2011-0411OC)

Weerackody, R. P., Welsh, D. J., Wadsworth, R. M. and Peacock, A. J. (2009) Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology: Heart and Circulatory Physiology, 296(5), H1312-H1320. (doi: 10.1152/ajpheart.00977.2008)

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117(22), pp. 2928-2937. (doi: 10.1161/CIRCULATIONAHA.108.767558)

Syyed, R., Reeves, J. T., Welsh, D., Raeside, D., Johnson, M. K. and Peacock, A. J. (2008) The Relationship Between the Components of Pulmonary Artery Pressure Remains Constant Under All Conditions in Both Health and Disease. Chest, 133(3), pp. 633-639. (doi: 10.1378/chest.07-1367)

Carlin, C., Peacock, A. and Welsh, D. (2007) Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 37(4), pp. 447-456. (doi: 10.1165/rcmb.2007-0012OC)

This list was generated on Mon Dec 6 19:54:16 2021 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Investigating the role of IL-33/ST2 signalling in the cardiac and vascular remodelling associated with pulmonary arterial hypertension
    British Heart Foundation
    2017 - 2021
     
  • Mechanisms underlying the development of pulmonary arterial hypertension
    Medical Research Council
    2013 - 2018
     
  • Acute Pulmonary Haemodynamic Effects of Apelin in Pulmonary Hypertension
    British Heart Foundation
    2012 - 2014
     
  • Wellcome VIP award
    Wellcome Trust
    2010 - 2010
     
  • Role of the fibroblast in pulmonary vascular remodelling: paracrine signalling and molecular mechanisms
    Wellcome Trust
    2009 - 2012